State of New Jersey Common Pension Fund D Buys 3,469 Shares of Azenta, Inc. (NASDAQ:AZTA)

State of New Jersey Common Pension Fund D raised its stake in Azenta, Inc. (NASDAQ:AZTA) by 9.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,008 shares of the company’s stock after purchasing an additional 3,469 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Azenta were worth $1,938,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Hantz Financial Services Inc. bought a new stake in Azenta in the 2nd quarter valued at $30,000. Farther Finance Advisors LLC lifted its holdings in shares of Azenta by 20.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock worth $74,000 after acquiring an additional 256 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Azenta by 150.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock worth $84,000 after acquiring an additional 955 shares during the period. Lazard Asset Management LLC bought a new position in shares of Azenta during the 1st quarter worth about $130,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Azenta by 24.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock worth $143,000 after acquiring an additional 471 shares during the period. 99.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Needham & Company LLC reduced their price objective on shares of Azenta from $69.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Evercore ISI reduced their price objective on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $63.60.

Azenta Stock Down 2.6 %

Shares of Azenta stock opened at $41.51 on Monday. The stock has a market capitalization of $2.03 billion, a P/E ratio of -13.98 and a beta of 1.48. The company has a 50-day simple moving average of $45.56 and a 200 day simple moving average of $50.43. Azenta, Inc. has a 12-month low of $40.24 and a 12-month high of $69.16.

Azenta (NASDAQ:AZTA) last announced its earnings results on Tuesday, November 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.08. The business had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $169.66 million. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the company posted $0.13 EPS. On average, equities analysts anticipate that Azenta, Inc. will post 0.4 earnings per share for the current year.

Insider Buying and Selling at Azenta

In other Azenta news, CFO Herman Cueto sold 1,595 shares of the firm’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total value of $69,669.60. Following the completion of the sale, the chief financial officer now owns 24,604 shares in the company, valued at approximately $1,074,702.72. This trade represents a 6.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.77% of the company’s stock.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.